Dr. Antoinette Wozniak is a medical thoracic oncologist at the UPMC Hillman Cancer Center. In addition to the Hillman Cancer Center, Dr. Wozniak is affiliated with UPMC Shadyside, UPMC Presbyterian and UPMC Magee-Womens Hospital.
Prior to bringing her skills to the UPMC Hillman Cancer Center, Dr. Wozniak worked as an oncologist in Detroit, Michigan. There she was associated with Karmanos Cancer Center, DMC Harper University Hospital and DMC – Detroit Receiving Hospital.
In addition to treating patients, including those diagnosed with mesothelioma cancer, Dr. Wozniak has published many studies and helped facilitate clinical trials relating to mesothelioma, other asbestos-related diseases and lung cancers.
Main Speciality: Thoracic Oncology
Other Interests & Specialties: Internal medicine and medical oncology.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Hematology, American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Internal Medicine, member of the International Association for the Study of Lung Cancer, member of the American College of Physicians, member of Southwest Oncology Group, member of American Society of Clinical Oncology and a member of the American Association of Cancer Research, Super Doc Award.
Education & Experience:
- Medical Degree from the State University of New York at Buffalo Jacobs School of Medicine, Buffalo, NY
- Residency at SUNY at Buffalo, Buffalo, NY
- Fellowship in Hematology and Medical Oncology at the University of Florida College of Medicine, Gainesville, FL
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. June 2016;11(6):900-909. doi: 10.1016/j.jtho.2016.02.006
Phase II Study of AZD2171 in Patients with Malignant Pleural Mesothelioma: SWOG S0509. Journal of Thoracic Oncology. November 2001;6(11):1938-1945. doi: 10.1097/JTO.0b013e318229586e
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer: SWOG S0533. Clinical Lung Cancer. September 2015;16(5):340-347. doi: 10.1016/j.cllc.2014.12.014
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs